Drug Combination Details
| General Information of the Combination (ID: C23448) | |||||
|---|---|---|---|---|---|
| Name | Silibinin NP Info | + | 1,25-dihydroxyvitamin D3 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colon cancer
[ICD-11: 2B90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | SNAI2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | VDR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
| SW480R | CVCL_AT68 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Silibinin restored 1,25D responsiveness in vitamin D-resistant colon cancer cells by downregulation of Snail1 and Snail2 and upregulation of vitamin D receptor. | |||||
